Skip to main content

Bristol Myers Squibb company profile

  • BMY · NYSE
  • Pharmaceuticals
  • S&P 500
$63.43+1.78%Close 13 Nov 2026 · Market value $128.5B

About Bristol Myers Squibb

Bristol Myers Squibb is a biopharmaceutical company that discovers, develops, licenses, manufactures, markets, distributes and sells medicines for serious diseases, operating in a single segment. Its focus areas include oncology, hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. Its marketed products include Opdivo, Eliquis, Breyanzi, Abecma, Reblozyl, Camzyos, Cobenfy and Sotyktu, among others, spanning small molecule drugs, biologics, CAR-T cell therapies and other modalities. The company sells its products worldwide, principally to wholesalers, distributors and specialty pharmacies, and to a lesser extent to retailers, hospitals, clinics, government agencies and patients directly. Significant manufacturing operations are located in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland.

A summary of the business section of the company's latest annual report, filed 11 Feb 2026.

Company facts

TickerBMY · NYSE
SectorPharmaceuticals
IndustryPharmaceuticals
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK14272
Latest annual report10-K, filed 11 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
D. V. ElkinsEVP, Chief Financial Officer190KOpen-market sale, 1 Apr 2026
J. Haller, M.D.Director135KOpen-market sale, 5 Nov 2026
S. Hirawat, M.D.EVP,Chief Med.Offr.,Drug Dev.31.9KOpen-market purchase, 25 Apr 2025
A. LenkowskyEVP, Chief Commercial Officer29.3KCode J, 1 May 2026
C. Massacesi, M.D.EVP,Chief Med Offr,Head of Dev0Open-market sale, 9 Sep 2026
Shanahan KarinEVP, Chief Supply Chain & Ops—Option exercise, 1 Nov 2026
Meyers Gregory ScottEVP, Chief Digital & Tech Off.—Option exercise, 1 Nov 2026
BOERNER CHRISTOPHER S.Chief Executive Officer · Director—Option exercise, 1 Nov 2026
Gallman CariEVP, General Counsel—Option exercise, 2 Oct 2026
Short Bartie WendyEVP, Corporate Affairs—Option exercise, 1 Sep 2026
Holzer Phil MSVP and Controller—Open-market sale, 25 Aug 2026
Hoch LynellePresident, Cell Therapy Org.—Option exercise, 10 Mar 2026
Poole Ahn AmandaEVP, Chief People Officer—Code J, 10 Mar 2026
Plenge Robert MEVP, Chief Research Officer—Shares withheld for tax, 10 Mar 2026
Hickey BenjaminPresident, RayzeBio Org.—Option exercise, 27 Feb 2026
LEUNG SANDRAEVP, General Counsel—Shares withheld for tax, 10 Mar 2025

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

BMY in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.